Please assess the completion status of the following clinical trial:

Trial Title: A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~• Patient with eosinophilic asthma who completed the treatment period of a double-blind, placebo controlled sc reslizumab study (Study C38072-AS-30025 or C38072-AS-30027)~\~\~ Additional criteria apply, please contact the investigator for more information~Exclusion Criteria:~* Patient has received any reslizumab administration in any previous clinical trial other than Studies C38072-AS-30025 and C38072-AS-30027.~* The patient has any clinically significant, uncontrolled medical condition~* The patient has another confounding underlying lung disorder~* The patient has a known/diagnosed hypereosinophilic syndrome.~* The patient has a diagnosis of malignancy within 5 years of the screening visit, except for treated and cured non-melanoma skin cancers.~* The patient is a pregnant or lactating woman~* The patient is a current smoker (ie, has smoked within the last 6 months before screening) or has a smoking history ≥10 pack-years.~* The patient is currently using any systemic immunosuppressive or immunomodulatory agents other than OCS~* The patient has a history of allergic reaction or hypersensitivity to any component of the study drug.~* The patient has a history of an immunodeficiency disorder including human immunodeficiency virus (HIV).~  * Additional criteria apply, please contact the investigator for more information

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- reslizumab 110 mg (Type: EXPERIMENTAL): Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upper arm(s) once every 4 weeks for a total of 9 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).